Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion
Open Access
- 25 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 16 (5) , 600-610
Abstract
Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling is one of the major pathways for cytokine signal transduction. However, the role of the JAK/STAT pathway in liver ischemia/reperfusion is not clear. This study focuses on Janus kinase-2 (JAK2), which functions upstream of signal transducer and activator of transcription 1 (STAT1) in JAK/STAT, and its role in the mechanism of liver ischemia/reperfusion injury (IRI). Partial warm ischemia was produced in the hepatic lobes of C57BL/6 mice for 90 minutes, and this was followed by 6 hours of reperfusion. Mice were treated with a JAK2 inhibitor (tyrphostin AG490; 40 mg/kg intraperitoneally) or vehicle 60 minutes prior to ischemic insult. JAK2 blockade resulted in a significant reduction of hepatocyte apoptosis and liver injury. Macrophage and neutrophil infiltration, as assessed by immunohistochemistry, was markedly decreased in AG490-treated livers in comparison with controls. The expression of pro-inflammatory cytokines [tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-1β] and chemokines [chemokine (C-X-C motif) ligand 10 (CXCL-10) and CXCL-2] was also significantly reduced in the AG490-treated group in comparison with controls. AG490-treated livers showed fewer cells positive for terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling and reduced cleaved caspase-3 protein expression in parallel with increased B-cell lymphoma extra large expression. We employed AG490 (75 mM) in primary bone marrow-derived macrophage (BMM) and hepatoma cell (CRL1830) cultures, which were both stimulated with lipopolysaccharide (LPS; 10 ng/mL). In BMM cultures, AG490 depressed otherwise LPS-induced pro-inflammatory gene expression programs (IL-6, IL-12p40, IL-1β, CXCL-10, and inducible nitric oxide synthase). In hepatoma cells, AG490 reduced cleaved caspase-3 expression. Moreover, JAK2 blockade inhibited STAT1 and STAT3 phosphorylation. This is the first report documenting that JAK2 signaling is essential in the pathophysiology of liver IRI, as its selective blockage ameliorated the disease process and protected livers from inflammation and apoptosis. Liver Transpl 16:600-610, 2010. © 2010 AASLD.Keywords
Funding Information
- National Institutes of Health (RO1 DK062357)
- Dumont Research Foundation
- Coordencao de Aperfeicoamento de Pessoal de Nivel Superior and the International Society of Nephrology
This publication has 54 references indexed in Scilit:
- Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicityKidney International, 2009
- Suppressor of cytokine signaling expression with increasing severity of murine hepatic ischemia-reperfusion injuryJournal of Hepatology, 2008
- Factors in the Pathophysiology of the Liver Ischemia-Reperfusion InjuryJournal of Surgical Research, 2008
- Essential Role for Signal Transducer and Activator of Transcription-1 in Pancreatic β-Cell Death and Autoimmune Type 1 Diabetes of Nonobese Diabetic MiceDiabetes, 2007
- Generation of hypochlorite-modified proteins by neutrophils during ischemia-reperfusion injury in rat liver: attenuation by ischemic preconditioningAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2005
- Type I and type II interferons delay human neutrophil apoptosis via activation of STAT3 and up-regulation of cellular inhibitor of apoptosis 2Journal of Leukocyte Biology, 2005
- 15-Epi-16-(Para-Fluorophenoxy)-Lipoxin A4-Methyl Ester, a Synthetic Analogue of 15-epi-Lipoxin A4, Is Protective in Experimental Ischemic Acute Renal FailureJournal of the American Society of Nephrology, 2002
- Ischemia-induced STAT-1 Expression and Activation Play a Critical Role in Cardiomyocyte ApoptosisJournal of Biological Chemistry, 2000
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Tyrosine Kinase Inhibition: An Approach to Drug DevelopmentScience, 1995